Top of this page
Skip navigation, go straight to the content

ucb-usa.com Responsibility U.S. Policy Value-Based Care
 

U.S. Public Policy Inspired by Patients: Value-Based Care

Supporting value-based care for patients

 

UCB is committed to ensuring patients receive value-based care through informed healthcare decision-making, value-based contracting and payment models, and patient-centered policy proposals that advance the shift of health policy and practice to better account for patient value. Enhanced focus on high-quality, high-value care is critical to improving patient lives.

 

Supporting informed healthcare decision-making

  • We believe patients should have the information they need to make informed decisions about their care; to further support this the regulatory process should reflect and recognize the value of sharing additional, balanced, non-misleading, and evidence-based healthcare information about medicines with patients and providers.

 

Collaborating with healthcare payers, providers, and policymakers to advance value-based care

  • We are committed to working across the healthcare ecosystem – with payers, providers, and policymakers - to explore a broad range of patient-driven contracting approaches that more clearly connect price to value and support smarter spending in the healthcare system. This shift requires new policies to create an environment more conducive to testing value-based care, such as creating flexibilities or establishing a value-based contracting pilot program with safe harbors and exemptions from current regulatory barriers.

 

Adopting market-based payments for healthcare that reward value and encourage continued innovation

  • We are committed to ensuring that policies do not undermine the healthcare system’s evolution to better account for value and allow and encourage continued investment in innovation for patients. Policies removing barriers to private market solutions are needed to further innovation, protect patient access, and promote the development of new life-changing medicines. Policies that inhibit competition, innovation, and value creation – such as those that impose price controls or require the disclosure of proprietary information – should be avoided.